Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury

Ren Fail. 2024 Dec;46(1):2307959. doi: 10.1080/0886022X.2024.2307959. Epub 2024 Jan 30.

Abstract

Background: Sepsis-associated acute kidney injury (S-AKI) is a critical illness and is often associated with high morbidity and mortality rates. The soluble urokinase-type plasminogen activator receptor (suPAR) is an important immune mediator and is involved in kidney injury. However, its diagnostic value in S-AKI patients remains unclear. Therefore, we assessed the early predictive value of suPAR for S-AKI patients.

Methods: We prospectively enrolled adult patients, immediately after fulfilling the sepsis-3 criteria. Plasma suPAR levels at 0-, 12-, 24-, and 48-h post-sepsis diagnosis were measured. S-AKI development was the primary outcome. S-AKI risk factors were analyzed using logistic regression, and the value of plasma suPAR for early S-AKI diagnosis was assessed using receiver operating characteristic (ROC) curves.

Results: Of 179 sepsis patients, 63 (35.2%) developed AKI during hospitalization. At 12-, 24-, and 48-h post-sepsis diagnosis, plasma suPAR levels were significantly higher in patients with S-AKI than in patients without S-AKI (p < 0.05). The plasma suPAR had the highest area under the ROC curve of 0.700 (95% confidence interval (CI), 0.621-0.779) at 24-h post-sepsis diagnosis, at which the best discrimination ability for S-AKI was achieved with suPAR of ≥6.31 ng/mL (sensitivity 61.9% and specificity 71.6%). Logistic regression analysis showed that suPAR at 24-h post-sepsis diagnosis remained an independent S-AKI risk factor after adjusting for mechanical ventilation, blood urea nitrogen, and pH.

Conclusions: The findings suggest that plasma suPAR may be a potential biomarker for early S-AKI diagnosis.

Keywords: Acute kidney injury; ICU; sepsis; soluble urokinase-type plasminogen activator receptor.

MeSH terms

  • Acute Kidney Injury* / diagnosis
  • Acute Kidney Injury* / etiology
  • Adult
  • Biomarkers
  • Critical Illness
  • Humans
  • Prognosis
  • ROC Curve
  • Receptors, Urokinase Plasminogen Activator
  • Sepsis* / complications
  • Sepsis* / diagnosis

Substances

  • Receptors, Urokinase Plasminogen Activator
  • Biomarkers

Grants and funding

This work was supported by the funding of Zhongyuan Scholars of Henan Provincial Health Commission under Grant [number 224000510005], the Henan Province Science and Technology Attack Plan Project under Grant [number 222102310429 and 212102310201], Zhongyuan Scholar Workstation under Grant [number 234400510024], and the National Natural Science Foundation of China under Grant [number 81770725].